• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Quick Take: The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults

byConstance WuandAliya Ramjaun
June 17, 2019
in Infectious Disease, Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

National survey reports parental views on COVID-19 vaccination in children

Tdap vaccine during pregnancy not linked to adverse childhood health outcomes

Novel OPV2-c1 and OPV2-c2 vaccines offer promising safety, tolerability, and immunogenicity in healthy adults

Oral live-attenuated polio vaccines (OPV) and injected inactivated polio vaccines IPV) have helped eradicate wild polioviruses. However, there is still a need to develop new vaccines due to risk of outbreaks of vaccine-derived polioviruses. In the process of developing new vaccines, it is important to study the safety of the viruses and possible release into the environment. In this double-blind phase 1 trial, investigators randomized 30 participants to receive two novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates in order to study the safety of the vaccines, the nature of viral shedding in participants, and the immunogenic effect of the vaccines. Investigators found that both OPV2 candidates increased the median blood titer of serum neutralizing antibodies, and all participants were seroprotected after vaccination. Severe events were reported in 40% of participants receiving candidate 1, and in 60% of participants receiving candidate 2; most events were increases in blood creatinine phosphokinase without accompanying clinical symptoms. There were no serious adverse events. In terms of shedding, 100% of participants receiving vaccine candidate 1 and 87% of participants receiving candidate 2 had vaccine virus detected in their stools. Viral shedding stopped after a median of 23 days (IQR 15-36 days) and 12 days (IQR 1-23) for candidates 1 and 2, respectively. Overall, the results from this study indicate an acceptable safety profile for the two vaccine candidates and a shedding rate that is not substantially increased compared to existing vaccines. As such, these candidates hold promise for future studies. Limitations for this study include the small sample size and the lack of placebo group.

Click to read the study in Lancet

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: immunizationslive vaccinepoliovaccines
Previous Post

Quick Take: Association of Cortical Stimulation–Induced Seizure With Surgical Outcome in Patients With Focal Drug-Resistant Epilepsy

Next Post

2 Minute Medicine Rewind June 17, 2019

RelatedReports

Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

National survey reports parental views on COVID-19 vaccination in children

September 14, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Tdap vaccine during pregnancy not linked to adverse childhood health outcomes

April 19, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Novel OPV2-c1 and OPV2-c2 vaccines offer promising safety, tolerability, and immunogenicity in healthy adults

January 13, 2021
#VisualAbstract: Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression
StudyGraphics

#VisualAbstract: Special Report: Vaccines in Development- Johnson & Johnson vaccine as another frontrunner

January 5, 2021
Next Post
Lower long-term IUD use among young women

2 Minute Medicine Rewind June 17, 2019

Increased complications associated with emergent repeat cesarean

Being denied a wanted abortion may have detrimental health effects in the long term

Prescription of antibiotics for acute respiratory infections increasing

Bacteremia in pediatric pneumonia associated with disease severity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.